Bernat Bertran Recasens is a neurologist working in the Neuromuscular Unit of the Hospital del Mar in Barcelona (Spain). His main area of clinical and scientific interest is Motor Neuron Diseases, performing patient care in the Multidisciplinary Motoneuron Unit.
From a research point of view, Bernat won a grant to identify clinical biomarkers of bulbar dysfunction and participates in international clinical trials. In addition, he has been one of the main writers of the guidelines for the management and treatment of Motor Neuron Disease of the Catalan Society of Neurology. He has carried out training stays at the Motor Neuron Unit of the Bellvitge Hospital, Barcelona (led by Dr Povedano), where he continues to collaborate, and at the Haukeland University Hospital in Norway (led by Dr Tysnes).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.